Sociodemographic and prescribing characteristics that impact long-term retention in buprenorphine treatment for opioid use disorder among a statewide population. (1st December 2022)

• Record Type: Journal Article
• Authors: Hallowell, Benjamin D.; Chambers, Laura C.; Samuels, Elizabeth A.; Bratberg, Jeffrey; McDonald, James; Nitenson, Adam; Onyejekwe, Collette; Beaudoin, Francesca L.
• Is Part Of: Drug and alcohol dependence. Volume 241(2022)
• Publication Date: 2022-12-01
• Subjects: Buprenorphine -- Opioid use disorder -- Opioid -- Retention -- Healthcare -- Prescription drug monitoring; Drug abuse -- Periodicals; Alcoholism -- Periodicals; 616.86
• DOI: 10.1016/j.drugalcdep.2022.109680
• Languages: English
• ISSNs: 0376-8716

Abstract

Abstract: Background and Aims: Partial opioid agonist medications for opioid use disorder reduce mortality and morbidity, however long-term retention in treatment is challenging. The objective of this study was to identify patient and prescription characteristics associated with long-term buprenorphine treatment retention. Methods: We used data from the Rhode Island prescription drug monitoring program to identify residents who initiated buprenorphine treatment and determine if they were retained in long-term buprenorphine treatment 12-months after treatment initiation. Multivariable logistic regression models were used to identify sociodemographic and prescription characteristics associated with long-term buprenorphine retention. Findings: During the study period 4898 unique Rhode Island residents initiated buprenorphine treatment, of whom 37.8 % were retained in treatment at 12-months. Demographic factors associated with a higher odds of long-term buprenorphine retention included older age, female sex, Medicaid insurance (vs private), and living closer to the pharmacy where the prescription was filled. Individuals who were prescribed the tablet formulation (aOR: 0.82 [95 % CI 0.72, 0.93]) or received a non-buprenorphine opioid during the follow-up window (aOR: 0.37 [95 % CI 0.31, 0.44]) had lower odds of long-term treatment at 12-months. Individuals who received at least one day of overlapping benzodiazepine and buprenorphine prescriptions (aOR: 2.00 [95 % CI 1.70, 2.34]) and those given a longer days supply (aOR: 1.26 [95 % CI 1.01, 1.56]) had higher odds of long-term treatment at 12-months. Findings were similar for treatment retention at 6-months in sensitivity analyses. Conclusions: These findings highlight several modifiable prescribing practices associated with long-term buprenorphine retention, suggesting that clinicians and public health practitioners can help remove barriers to long-term retention. Highlights: 37.8 % of buprenorphine initiates were retained in treatment at 12-months. Film buprenorphine formulations (vs tablet) resulted in higher treatment retention. Individuals who lived further from the pharmacy had lower treatment retention. Individuals dispensed a non-buprenorphine opioid during follow-up had lower treatment engagement.